Dhiraj Bhatia
@iitgn.ac.in
Assistant Professor, Biological Engineering Discipline
Indian Institute of Technology Gandhinagar
EDUCATION
PhD, NCBS_TIFR
RESEARCH, TEACHING, or OTHER INTERESTS
Multidisciplinary, Biotechnology
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Rahul Sharma, Unnati Modi, Rahul Kumar, Chirag Sharma, Amit Kumar Srivastav, Dhiraj Bhatia, and Raghu Solanki
Elsevier BV
P. Chithra, Dhiraj Bhatia, and Raghu Solanki
Elsevier BV
Rohit Gupta, Anvesh Gaddam, Hema Naveena A, Deepak Prajapati, Stefan Dimov, Dhiraj Bhatia, Abhijit Mishra, Yavor Sofronov, and Madhu Vadali
Elsevier BV
Deepika Chauhan, Amit K. Yadav, Dhiraj Bhatia, and Pratima R. Solanki
Elsevier BV
Rohan Vishwanath, Abhijit Biswas, Unnati Modi, Sharad Gupta, Dhiraj Bhatia, and Raghu Solanki
Royal Society of Chemistry (RSC)
The schematic representation of biomedical applications of short peptides in cancer therapy, regenerative medicine, and tissue engineering.
Nihal Singh, Ankur Singh, and Dhiraj Bhatia
American Chemical Society (ACS)
Ewan MacDonald, Alison Forrester, Cesar A. Valades-Cruz, Thomas D. Madsen, Joseph H. R. Hetmanski, Estelle Dransart, Yeap Ng, Rashmi Godbole, Ananthan Akhil Shp, Ludovic Leconte,et al.
Springer Science and Business Media LLC
Krupa Kansara, Anwesha Laha, Ashutosh Kumar, and Dhiraj Bhatia
Wiley
AbstractDeoxyribonucleic acid (DNA) nanotechnology has brought an unparalleled set of possibilities for self‐assembled structures emerging as an independent branch of synthetic biology. The field of science uses the molecular properties of DNA to build nanoparticles and nanodevices that have the potential to bring breakthroughs in medical science. On the one hand, their biocompatibility, precision, synthetic ease, and programmability make them an ideal choice in drug delivery and healthcare. On the other, the lack of proper biodistribution profiles, stability inside the system, enzymatic cleavage, immune recognition, and translational barriers are some of the hurdles it faces. Many recent technological advancements are in progress to tackle these challenges, while some already have been used. These tools and technologies need to be understood and studied for the successful transition of these intelligent DNA nanostructures (DNs) to healthcare applications. This review thus, highlights some of the challenges being faced by the DNs in healthcare. Additionally, it provides an overview of the recent trends in using these devices in disease detection and remission and finally talks about the future scope and opportunities for an effective transition from bench to bedside.
Parul Singh, Hitasha Vithalani, Aditya Adhyapak, Tinodaishe Semwa, Nihal Singh, Mukesh Dhanka, Dhiraj Bhatia, and Jhuma Saha
Springer Science and Business Media LLC
Nihal Singh, Ayushi Sharma, Anjana Goel, Krishan Kumar, Raghu Solanki, and Dhiraj Bhatia
Wiley
AbstractDNA nanotechnology represents an innovative discipline that combines nanotechnology with biotechnology. It exploits the distinctive characteristics of deoxyribonucleic acid (DNA) to create nanoscale structures and devices with remarkable accuracy and functionality. Researchers may create complex nanostructures with precision and specialized functions using DNA's innate stability, adaptability, and capacity to self‐assemble through complementary base‐pairing interactions. Integrating multiple disciplines, known as nanobiotechnology, allows the production of sophisticated nanodevices with a broad range of applications. These include precise drug delivery systems, extremely sensitive biosensors, and the construction of intricate tissue scaffolds for regenerative medicine. Moreover, combining DNA nanotechnology with mechanobiology provides a new understanding of how small‐scale mechanical stresses and molecular interactions affect cellular activity and tissue development. DNA nanotechnology has the potential to revolutionize molecular diagnostics, tissue engineering, and organ regeneration. This could lead to enormous improvements in biomedicine. This review emphasizes the most recent developments in DNA nanotechnology, explicitly highlighting its significant influence on mechanobiology and its growing involvement in organ engineering. It provides an extensive overview of present trends, obstacles, and future prospects in this fast‐progressing area.
Ankesh Kumar, Pankaj Yadav, and Dhiraj Bhatia
World Scientific Pub Co Pte Ltd
Nanodiamonds (NDs) have unique optical and mechanical characteristics, surface chemistry, extensive surface area and biocompatibility, and they are nontoxic, rendering them suitable for a diverse range of applications. Recently, NDs have received significant attention in nano-biomedical engineering. This review discusses the recent advancement of NDs’ biomedical engineering, historical background, basic introduction to nanoparticles and development. We summarize NDs’ synthesis technique, properties and applications. Two methodologies are used in ND synthesis: bottom-up and top-down. We cover synthesis methods, including detonation, ball milling, laser ablation, chemical vapor deposition (CVD) and high pressure and high temperature (HPHT); discuss the properties of NDs, such as fluorescence and biocompatibility. Due to these properties, NDs have potential applications in biomedical engineering, including bioimaging, biosensing, drug delivery, tissue engineering and protein mimics. Further, it provides an outlook for future progress, development and application of NDs in biological and biomedical areas.
Raj Dave, Kshipra Pandey, Ritu Patel, Nidhi Gour, and Dhiraj Bhatia
Springer Science and Business Media LLC
Ankur Singh, Nihal Singh, Manasi Esther Jinugu, Prachi Thareja, and Dhiraj Bhatia
Elsevier BV
Geethu Prakash, Bhagyesh Parmar, and Dhiraj Bhatia
Royal Society of Chemistry (RSC)
The application of nanotechnology in medical biology has seen a significant rise in recent years because of the introduction of novel tools that include supramolecular systems, complexes, and composites.
Jaydeepsinh Chavda, Arjun Siwach, Sudhir Sabharwal, Anu Janaagal, Dhiraj Bhatia, and Iti Gupta
American Chemical Society (ACS)
Raj Dave, Kshipra Pandey, Sweny Jain, Vivekshinh Kshtriya, Poulomi Sengupta, Sandeep Kumar Verma, Nidhi Gour, and Dhiraj Bhatia
Wiley
AbstractThe environment consists of wide diversity, of which, an integral and most diversifying part is the living organisms, and hence it is imperative to design novel strategies that could alleviate pollutants and detect them at very minute levels. The functionalization of nanomaterials provides a very facile and efficient tool for the design of robust sensors that could detect pollutants that contaminate air, water, and soil. Because of their nanoscale size, these materials have enhanced surface‐to‐volume ratio, which in turn provide more reaction sites for the analyte interaction and enables highly specific and sensitive detection. Different nanomaterials like metal/metal oxide nanoparticles, quantum dots, carbon‐based nanomaterials, and miscellaneous nanomaterials like polymer, dendrimers, metal‐organic frameworks are functionalized with suitable ligands for efficient detection of a wide range of pollutants such as heavy metals, pesticides, industrial wastes, volatile organic compounds, toxic gases, and environmental pathogens with efficient level of sensitivity. In this review, we will briefly discuss different types of functionalized nanomaterials, strategies adopted for their functionalization, detection methodologies pursued for specific sensing and detection of different types of pollutants and their critical analysis, and future outlook.
Raghu Solanki, Nilesh Makwana, Rahul Kumar, Madhvi Joshi, Ashish Patel, Dhiraj Bhatia, and Dipak Kumar Sahoo
Royal Society of Chemistry (RSC)
Antimicrobial mechanism of nanomaterials to combat AMR.
Bhagyesh Parmar and Dhiraj Bhatia
American Chemical Society (ACS)
Utilizing induced pluripotent stem cells (iPSCs) in drug screening and cell replacement therapy has emerged as a method with revolutionary applications. With the advent of patient-specific iPSCs and the subsequent development of cells that exhibit disease phenotypes, the focus of medication research will now shift toward the pathology of human diseases. Regular iPSCs can also be utilized to generate cells that assess the negative impacts of medications. These cells provide a much more precise and cost-efficient approach compared to many animal models. In this review, we explore the utilization of small-molecule drugs to enhance the growth of iPSCs and gain insights into the process of reprogramming. We mainly focus on the functions of small molecules in modulating different signaling pathways, thereby modulating cell fate. Understanding the way small molecule drugs interact with iPSC technology has the potential to significantly enhance the understanding of physiological pathways in stem cells and practical applications of iPSC-based therapy and screening systems, revolutionizing the treatment of diseases.
Nitumani Tripathi, Payal Vaswani, Dhiraj Bhatia, Ketan Kuperkar, and Pratap Bahadur
Springer Science and Business Media LLC
Ashwin Rajeev and Dhiraj Bhatia
Royal Society of Chemistry (RSC)
After the discovery of DNA during the mid-20th century, a multitude of novel methodologies have surfaced which exploit DNA for its various properties.
Ayushi Sharma and Dhiraj Bhatia
Royal Society of Chemistry (RSC)
Cancer immunotherapy involves a cutting-edge method that utilizes the immune system to detect and eliminate cancer cells.
Simran Nasra, Dhiraj Bhatia, and Ashutosh Kumar
Wiley
AbstractRheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation and destruction. Current treatments, such as Methotrexate (MTX), though effective, often face limitations such as high plasma Cmax and lack of sustained release. This study explores a synergistic approach to RA therapy using folate‐liposomal co‐delivery of MTX and RELA siRNA (short interfering RNA), targeting RAW264.7 macrophage repolarization via nuclear factor kappa B (NF‐κB) pathway inhibition. Extensive in vitro characterizations demonstrate the stability and biocompatibility of this therapy via folate‐liposomes. In the collagen‐induced arthritis (CIA) rat model, treatment leads to reduced synovial inflammation and improved mobility. The combined MTX and RELA siRNA approach indirectly inhibits inflammatory cytokines, rheumatoid factor (RF), and C‐reactive protein (CRP). Targeted macrophage delivery shows marked therapeutic effects in RAW264.7 murine macrophages, potentially modulating M1 to M2 polarization. This research presents a promising avenue for innovative RA therapies by inhibiting the inflammatory cascade and preventing joint damage.